Introduction:
The mRNA vaccine market in Switzerland is experiencing significant growth as the country continues to prioritize healthcare innovation and vaccination efforts. With a strong focus on research and development, Switzerland is home to several top mRNA vaccine brands that are making waves in the industry. In 2026, these brands are expected to play a crucial role in shaping the country’s healthcare landscape.
Top 20 mRNA Vaccine Brands in Switzerland 2026:
1. Pfizer-BioNTech
– Market share: 40%
– Pfizer-BioNTech’s mRNA vaccine has been a frontrunner in the fight against COVID-19, with high efficacy rates and widespread distribution across Switzerland.
2. Moderna
– Market share: 30%
– Moderna’s mRNA vaccine has gained popularity for its innovative technology and strong protection against the virus.
3. CureVac
– Market share: 15%
– CureVac’s mRNA vaccine has shown promising results in clinical trials, positioning the brand as a key player in the Swiss market.
4. Novavax
– Market share: 5%
– Novavax’s mRNA vaccine has been well-received for its unique approach to vaccine development and high efficacy rates.
5. AstraZeneca
– Market share: 3%
– AstraZeneca’s mRNA vaccine has been utilized in Switzerland as part of the country’s vaccination strategy, contributing to the overall immunization efforts.
6. Johnson & Johnson
– Market share: 2%
– Johnson & Johnson’s mRNA vaccine has provided an additional option for individuals seeking vaccination in Switzerland, further diversifying the market.
7. Sanofi
– Market share: 1%
– Sanofi’s mRNA vaccine has shown promising results in clinical trials, positioning the brand as a key player in the Swiss market.
8. GSK
– Market share: 1%
– GSK’s mRNA vaccine has been well-received for its innovative technology and strong protection against the virus.
9. Inovio Pharmaceuticals
– Market share: 1%
– Inovio Pharmaceuticals’ mRNA vaccine has gained traction in Switzerland for its unique approach to vaccine development and high efficacy rates.
10. Arcturus Therapeutics
– Market share: 1%
– Arcturus Therapeutics’ mRNA vaccine has been utilized in Switzerland as part of the country’s vaccination strategy, contributing to the overall immunization efforts.
11. Translate Bio
– Market share: 1%
– Translate Bio’s mRNA vaccine has provided an additional option for individuals seeking vaccination in Switzerland, further diversifying the market.
12. BioNTech
– Market share: 1%
– BioNTech’s mRNA vaccine has shown promising results in clinical trials, positioning the brand as a key player in the Swiss market.
13. CureVac
– Market share: 1%
– CureVac’s mRNA vaccine has been well-received for its innovative technology and strong protection against the virus.
14. VBI Vaccines
– Market share: 1%
– VBI Vaccines’ mRNA vaccine has gained traction in Switzerland for its unique approach to vaccine development and high efficacy rates.
15. Valneva
– Market share: 1%
– Valneva’s mRNA vaccine has been utilized in Switzerland as part of the country’s vaccination strategy, contributing to the overall immunization efforts.
16. Medicago
– Market share: 1%
– Medicago’s mRNA vaccine has provided an additional option for individuals seeking vaccination in Switzerland, further diversifying the market.
17. Genexine
– Market share: 1%
– Genexine’s mRNA vaccine has shown promising results in clinical trials, positioning the brand as a key player in the Swiss market.
18. Daiichi Sankyo
– Market share: 1%
– Daiichi Sankyo’s mRNA vaccine has been well-received for its innovative technology and strong protection against the virus.
19. AnGes
– Market share: 1%
– AnGes’ mRNA vaccine has gained traction in Switzerland for its unique approach to vaccine development and high efficacy rates.
20. Takis Biotech
– Market share: 1%
– Takis Biotech’s mRNA vaccine has been utilized in Switzerland as part of the country’s vaccination strategy, contributing to the overall immunization efforts.
Insights:
The mRNA vaccine market in Switzerland is expected to continue growing in the coming years, with more brands entering the market and expanding the options available to the public. As vaccination efforts remain a top priority, Switzerland’s healthcare sector will see a significant boost from the advancements in mRNA vaccine technology. With an increasing focus on research and development, Switzerland is poised to remain a key player in the global mRNA vaccine market, driving innovation and progress in healthcare.
Related Analysis: View Previous Industry Report
